3.
Guan
WJ,
Liang
WH,
Zhao
Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in
China: A Nationwide Analysis. European respiratory Journal 2020;
DOI:10.1183/13993003.00547-2020.
4. Fadini GP, Morieri ML, Longato E, et al. Prevalence and impact of
diabetes among people infected with SARS‐CoV‐2. J Endocrinol Invest
2020; 43: 867-9.
5. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular
metabolic diseases on COVID‐19 in China. Clin Res Cardiol 2020; 109:
531-8.
6. Yang J, Zhen Y, Gou X, et al. Prevalence of comorbidities and its
effects in patients infected with SARS-CoV-2: a systematic review and
meta-analysis. Int J Infect Dis 2020; 94: 91-5.
7. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al.
Clinical, laboratory and imaging features of COVID-19: A systematic
review and meta-analysis. Travel Med Infect Dis 2020; 34: 101623.
doi:10.1016/j.tmaid.2020.101623.